Summit has entered into a new revenue share agreement with the Wellcome Trust for ridinilazole for the treatment of C. difficile infection (CDI). The Wellcome Trust has played an incredibly supportive role in the development of ridinilazole to date through multiple grants. We view the new terms of the agreement as more favourable to Summit as it progresses the antibiotic towards Phase III. We look forward to the commencement of two Phase III trials in H1 2018.
06 Nov 2017
N+1 Singer - Summit Therapeutics - Revenue share agreement with the Wellcome Trust
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Summit Therapeutics - Revenue share agreement with the Wellcome Trust
Summit has entered into a new revenue share agreement with the Wellcome Trust for ridinilazole for the treatment of C. difficile infection (CDI). The Wellcome Trust has played an incredibly supportive role in the development of ridinilazole to date through multiple grants. We view the new terms of the agreement as more favourable to Summit as it progresses the antibiotic towards Phase III. We look forward to the commencement of two Phase III trials in H1 2018.